Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Hypertension management is crucial for reducing cardiovascular events.
• Initial combination therapy is a strategy for achieving blood pressure control.
• The ACCOMPLISH trial investigated specific drug combinations for high-risk patients.

Purpose of the Study:

• To review the ACCOMPLISH trial results comparing ACEI/CCB and ACEI/diuretic therapy.
• To explore the applicability of ACCOMPLISH findings to other renin-angiotensin-aldosterone system (RAAS) inhibitor/CCB combinations, including angiotensin receptor blockers (ARBs).
• To support the use and further investigation of RAAS inhibitor/CCB combination therapies.

Main Methods:

• Review of the ACCOMPLISH trial data on cardiovascular outcomes.
• Analysis of trials comparing angiotensin receptor blocker (ARB) and angiotensin-converting enzyme inhibitor (ACEI) therapies.
• Examination of studies on ARB/calcium channel blocker (CCB) combination therapy.

Main Results:

• Initial fixed-dose combination therapy, particularly ACEI/CCB, proved effective in reducing cardiovascular events in high-risk hypertensive patients.
• ACEI/CCB therapy demonstrated the greatest benefit in risk reduction compared to ACEI/diuretic therapy.
• The study highlights the potential of RAAS inhibitor/CCB combinations.

Conclusions:

• The ACCOMPLISH trial established the efficacy of ACEI/CCB initial combination therapy for high-risk hypertension.
• Further research is warranted to confirm the benefits of other RAAS inhibitor/CCB combinations, such as ARB/CCB.
• Combination therapy with RAAS inhibitors and CCBs holds promise for cardiovascular event prevention.